Fuhong Hanxuan "Adamu single resistance" was approved for listing

On December 7, the latest approval of NMPA showed that Fuhong Hanxuan "Adamu single anti-injection" was approved for market, becoming the fourth domestic Adamu single anti-biosynthic drug.
Adamu monoantigen (Shumeile) is the first fully humanized anti-tumor necrotic necrotic device developed by Abbvie, α (TNF-α), which was first approved for domestic import on February 26, 2010, and its antibody sequence patent expires in China in 2017.
In China, Shumei is pleased to be listed in 2010 and is currently approved for 3 adaptations of moderate to severe rheumatoid arthritis in adults, moderate to severe orthosis in adults with poor routine treatment, and severe chronic plaque-like psoriasis in adulthood.
addition, Shumeile was included in the CDE's March 2019 List of The Second Batch of Clinically Urgently Needed Foreign Drugs for the Treatment of Vine membraneitis.
During the 2019 health care negotiations, Shumeile's price reduction of 59% was successful, after Shumeile has been actively reduced from 7641.52 yuan to 3160 yuan, a cumulative decline of more than 83%, which will bring great competitive pressure to subsequent approval of domestic bioso-like drugs.
November 7, 2019, the first domestic Adamu monobial-like drug was approved for sale from Biotay (commodity name: Greeley), and on December 6, the same year, Haizheng Pharmaceuticals' Adamo monobiotic biosychic drug was approved (commodity name: Anjianin).
The Insight database shows that the three currently listed Adamo monobial-like drugs are priced consistently, all at $1,150/branch/0.8ml:40mg.
2020, the half-yearly report shows that Greeley's domestic sales in the third quarter were 57.7 million yuan, with cumulative sales of 100 million yuan in the first three quarters.
With the success of the original research into health care, the penetration rate of the domestic market is expected to further increase, according to Frost Sullivan reported that China's Adamo monobial similar drug market is expected to increase to 4.7 billion yuan in 2023, and will reach 11.5 billion yuan in 2030, if the marketing is done well may be a piece of the pie.
At present, the domestic Adamo single anti-biosynthic drug research and development is very hot, in addition to Baiotai, Haizheng, Fuhong Hanyu and Xinda, Junshi biological, Zhengtianqing biosychic drugs are also on the market review and approval.
Adamu single anti-biosynthic drugs in the research enterprises () from the figure above can be seen, adamo single anti-biosynthic drugs in the domestic research enterprises more than 20, the variety in the domestic competition has been white heat.
And on the relevant developments of the National Health Insurance Administration, it is currently studying the relevant policies for centralized procurement of biological products, biosynthic drugs are not a restricted area for centralized procurement, on the basis of taking into account the similarity of biosynthic drugs, the stability of enterprise capacity and supply chain, clinical alternatives to specific products and other factors, will be carried out in due course.
Thus, the collection of bio-similar drugs is also imminent, according to Insight database statistics, currently in line with the collection of bio-similar drugs in Adamo single resistance bear the brunt, followed by beva bead monoanti and lytices monoantigen resistance, but the industry also had expectations of this, but when the collection really arrived estimated to be a blood rain.
。